R Ienca1, C Giardiello2, A Scozzarro3, R Schiano di Cola2, N Di Lorenzo3, Girish Juneja4, G Lopez5, F Badiuddin6. 1. Elipse Weight Management Center, Nuova Villa Claudia Clinic, Via Flaminia Nuova, 280, Rome, Italia. roberta.ienca@gmail.com. 2. Emergency and Metabolic Surgery Dept, Pineta Grande Hospital, Via Domitiana Km. 30,00, Caserta, Italy. 3. Department of Surgical Science, Torvergata University, Viale Oxford 81, Rome, Italy. 4. Bariatric Center, Al Zahra Hospital, Al Barsha, Dubai, UAE. 5. Center for Strategic Healthcare Development, Dubai Science Park, Dubai, UAE. 6. Surgical Division, BR Medical Suites, Healthcare City, Dubai, UAE.
Abstract
BACKGROUND: Post intragastric balloon placement symptoms like nausea and vomiting have been the major cause of a high rate of early removal. Common therapy with ondansetron alone, or in combination, with prokinetic agents have been shown to have very little or no effect. Recently, an improved therapy based on aprepitant and ondansetron combination showed a significant improvement in symptoms management. Lack of aprepitant availability in several countries and patients difficulties to follow the right prescription convinced us to explore other pharmacological options. OBJECTIVE: Evaluate safety and efficacy of a netupitant and palonosetron-combined drug and to reduce and control post Elipse® placement symptoms METHODS: Between January and March 2018, 30 patients (9 male, 21 female), (mean weight 97.8 and mean BMI 34.7), underwent Elispe® placements, at 550 ml volume, in an outpatient fashion. All patients received a single pill 300 mg netupitant/0.5 mg palonosetron 6 h prior to placement. All patients received ondansetron 4 mg prescription to be taken as needed. A daily VAS score to report intensity of nausea, vomit, cramps, gastric pain, satiety for the first week post-placement was completed. RESULTS: 4/30 (13%) reported vomiting on days 1, 2, and 3; 9/30 (30%) reported nausea higher than score 4 on days 1, 2, and 3; 8/30 (26.6%) reported gastric pain higher than score 4 on days 1, 2, and 3. CONCLUSION: In our experience, the use of a single-pill netupitant/palonosetron resulted to be very easy to administer and effective in reducing vomit, nausea, and gastric pain in 87%, 70%, and 73.4% patients respectively, ameliorating the post Elipse™ placements symptoms safely.
BACKGROUND: Post intragastric balloon placement symptoms like nausea and vomiting have been the major cause of a high rate of early removal. Common therapy with ondansetron alone, or in combination, with prokinetic agents have been shown to have very little or no effect. Recently, an improved therapy based on aprepitant and ondansetron combination showed a significant improvement in symptoms management. Lack of aprepitant availability in several countries and patients difficulties to follow the right prescription convinced us to explore other pharmacological options. OBJECTIVE: Evaluate safety and efficacy of a netupitant and palonosetron-combined drug and to reduce and control post Elipse® placement symptoms METHODS: Between January and March 2018, 30 patients (9 male, 21 female), (mean weight 97.8 and mean BMI 34.7), underwent Elispe® placements, at 550 ml volume, in an outpatient fashion. All patients received a single pill 300 mg netupitant/0.5 mg palonosetron 6 h prior to placement. All patients received ondansetron 4 mg prescription to be taken as needed. A daily VAS score to report intensity of nausea, vomit, cramps, gastric pain, satiety for the first week post-placement was completed. RESULTS: 4/30 (13%) reported vomiting on days 1, 2, and 3; 9/30 (30%) reported nausea higher than score 4 on days 1, 2, and 3; 8/30 (26.6%) reported gastric pain higher than score 4 on days 1, 2, and 3. CONCLUSION: In our experience, the use of a single-pill netupitant/palonosetron resulted to be very easy to administer and effective in reducing vomit, nausea, and gastric pain in 87%, 70%, and 73.4% patients respectively, ameliorating the post Elipse™ placements symptoms safely.
Entities:
Keywords:
Anti-emetic drug; Balloon side effects; Elispe balloon; Intra-gastric balloon; Intra-gastric balloon drug therapy; Nausea; Obesity; Overweight; Vomiting; Weight loss
Authors: Matti Aapro; Karin Jordan; Richard J Gralla; Giada Rizzi; Giorgia Rossi; Marco Palmas; Anna V Alyasova; Alla S Lisyanskaya; Snežana M Bošnjak; Paul J Hesketh Journal: J Geriatr Oncol Date: 2016-11-23 Impact factor: 3.599
Authors: Jaime Ponce; George Woodman; James Swain; Erik Wilson; Wayne English; Sayeed Ikramuddin; Eric Bour; Steven Edmundowicz; Brad Snyder; Flavia Soto; Shelby Sullivan; Richard Holcomb; John Lehmann Journal: Surg Obes Relat Dis Date: 2014-12-16 Impact factor: 4.734
Authors: A Genco; T Bruni; S B Doldi; P Forestieri; M Marino; L Busetto; C Giardiello; L Angrisani; L Pecchioli; P Stornelli; F Puglisi; M Alkilani; A Nigri; N Di Lorenzo; F Furbetta; A Cascardo; M Cipriano; M Lorenzo; N Basso Journal: Obes Surg Date: 2005-09 Impact factor: 4.129
Authors: Iñaki Imaz; Carmen Martínez-Cervell; Elvira Elena García-Alvarez; Juan Manuel Sendra-Gutiérrez; Jesús González-Enríquez Journal: Obes Surg Date: 2008-05-06 Impact factor: 4.129
Authors: Evzen Machytka; Shantanu Gaur; Ram Chuttani; Martina Bojkova; Tomas Kupka; Marek Buzga; Andreas Giannakou; Kandiliotis Ioannis; Elisabeth Mathus-Vliegen; Samuel Levy; Ioannis Raftopoulos Journal: Endoscopy Date: 2016-12-12 Impact factor: 10.093